Perceived relevance of genetic carrier screening: Observations of the role of health-related life experiences and stage of life in decision making

Journal of Community Genetics

Volumn 3, Issue 1, 2012, Pages 47-54

  Archibald, Alison D ^a,b   McClaren, Belinda J ^a,b  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AWARENESS; CYSTIC FIBROSIS; DECISION MAKING; FRAGILE X SYNDROME; GENETIC SCREENING; HEALTH BEHAVIOR; HETEROZYGOTE DETECTION; HUMAN; MEDICAL INFORMATION; NOTE; OBSERVATIONAL METHOD; PERSONAL EXPERIENCE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; REPRODUCTION;

EID: 84863108389     PISSN: 1868310X     EISSN: 18686001     Source Type: Journal    
DOI: 10.1007/s12687-011-0067-8     Document Type: Note

References (44)

1. Abel K, Browner C (1998) Selective compliance with biomedical authority and the uses of experiential knowledge. In: Lock M, Kaufert P (eds) Pragmatic women and body politics. Cambridge University Press, Cambridge, pp 310-326
2. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, Holden JJ, Yang KT, Lee C, Hudson R, Gorwill H, Nolin SL, Glicksman A, Jenkins EC, Brown WT, Howard-Peebles PN, Becchi C, Cummings E, Fallon L, Seitz S, Black SH, Vianna-Morgante AM, Costa SS, Otto PA, Mingroni-Netto RC, Murray A, Webb J, MacSwinney F, Dennis N, Jacobs PA, Syrrou M, Georgiou I, Patsalis PC, Giovannucci U, Guarducci S, Lapi E, Cecconi A, Ricci U, Ricotti G, Biondi C, Scarselli B, Vieri F (1999) Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study - preliminary data. Am J Med Genet 83(4):322-325 (Pubitemid 29162637)
3. Archibald AD, Wilfond BS (2006) Population carrier screening: psychological impact. Wiley, New York
4. Archibald AD, Jaques AM, Wake S, Collins VR, Cohen J, Metcalfe SA (2009) "It's something I need to consider": decisions about carrier screening for fragile X syndrome in a population of nonpregnant women. Am J Med Genet A 149A(12):2731-2738
5. Barlow-Stewart K, Burnett L, Proos A, Howell V, Huq F, Lazarus R, Aizenberg H (2003) A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet 40(4):e45
6. Bekker H, Modell M, Denniss G, Silver A, Mathew C, Bobrow M, Marteau T (1993) Uptake of cystic fibrosis testing in primary care: supply push or demand pull? Br Med J 306(6892):1584
7. Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD (2011) Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 3(65):65ra64
8. Brookfield SD (1996) Adult learning: an overview. In: Tuijman AC (ed) International encyclopedia of education and training, 2nd edn. Pergamon, Tarrytown
9. Chen LS, Goodson P (2007) Factors affecting decisions to accept or decline cystic fibrosis carrier testing/screening: a theory-guided systematic review. Genet Med 9(7):442
10. Christie LM, Zilliacus EM, Ingrey AJ, Turner G (2006) Screening couples for cystic fibrosis carrier status: why are we waiting? Med J Aust 184(9):477 (Pubitemid 43676315)
11. Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell P (1996) Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet 58 (3):617
12. Cronister A, DiMaio M, Mahoney MJ, Donnenfeld AE, Hallam S (2005) Fragile X syndrome carrier screening in the prenatal genetic counseling setting. Genet Med 7(4):246
13. d'Agincourt-Canning L (2005) The effect of experiential knowledge on construction of risk perception in hereditary breast/ovarian cancer. J Genet Couns 14(1):55-69 (Pubitemid 40543822)
14. Delatycki MB (2008) Population screening for reproductive risk for single gene disorders in Australia: now and the future. Twin Res Hum Genet 11(4):422-430
15. Dodge JA, Lewis PA, Stanton M, Wilsher J (2007) Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 29 (3):522-526 (Pubitemid 46372100)
16. Etchegary H, Potter B, Howley H, Cappelli M, Coyle D, Graham I, Walker M, Wilson B (2008) The influence of experiential knowledge on prenatal screening and testing decisions. Genet Test 12(1):115-124 (Pubitemid 351457786)
17. Gason AA, Metcalfe SA, Delatycki MB, Petrou V, Sheffield E, Bankier A, Aitken M (2005) Tay Sachs disease carrier screening in schools: educational alternatives and cheekbrush sampling. Genet Med 7(9):626-632 (Pubitemid 41753014)
18. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S (2003) Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet 11(Suppl 2): S49-S87 (Pubitemid 38263569)
19. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ (2001) Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57(1):127-130 (Pubitemid 32634862)
20. Hantash FM, Goos DM, Crossley B, Anderson B, Zhang K, Sun W, Strom CM (2011) FMR1 premutation carrier frequency in patients undergoing routine population-based carrier screening: Insights into the prevalence of fragile X syndrome, fragile X-associated tremor/ataxia syndrome, and fragile X-associated primary ovarian insufficiency in the United States. Genet Med 13(1):39
21. Henneman L, Bramsen I, van Kempen L, van Acker MB, Pals G, van der Horst HE, Adèr HJ, van der Ploeg HM, ten Kate LP (2003) Offering preconceptional cystic fibrosis carrier couple screening in the absence of established preconceptional care services. Community Genetics 6(1):5-13 (Pubitemid 36693833)
22. Hill MK, Archibald AD, Cohen J, Metcalfe SA (2010) A systematic review of population screening for fragile X syndrome. Genet Med 12(7):396
23. Hodgson J, Weil J (2011) Talking about disability in prenatal genetic counseling: a report of two interactive workshops. J Genet Couns. doi:10.1007/s10897-011-9410-9.
24. Human Genetics Society of Australasia Genetic Services Committee (2009) Cystic fibrosis population screening position paper. Human Genetics Society of Australasia Genetic Services Committee, Alexandria
25. Ioannou L, Massie J, Collins V, McClaren B, Delatycki MB (2010) Population-based genetic screening for cystic fibrosis: attitudes and outcomes. Public Health Genomics 13(7-8):449-456
26. Janz NK, Becker MH (1984) The health belief model: a decade later. Health Educ Behav 11(1):1
27. Kolb DA (1984) Experiential learning: experience as the source of learning and development. Prentice Hall, Englewood Cliffs
28. Lippman A (1999) Embodied knowledge and making sense of prenatal diagnosis. J Genet Couns 8(5):255-273
29. Massie J, Forbes R, Dusart D, Bankier A, Delatycki MB (2007) Community-wide screening for cystic fibrosis carriers could replace newborn screening for the diagnosis of cystic fibrosis. J Paediatr Child Health 43(11):721-723 (Pubitemid 47537624)
30. Massie J, Petrou V, Forbes R, Curnow L, Ioannou L, Dusart D, Bankier A, Delatycki M (2009) Population-based carrier screening for cystic fibrosis in Victoria: the first three years experience. Aust N Z J Obstet Gynaecol 49(5):484-489
31. McClaren BJ, Delatycki MB, Collins V, Metcalfe SA, Aitken M (2008) 'It is not in my world': an exploration of attitudes and influences associated with cystic fibrosis carrier screening. Eur J Hum Genet 16(4):435-444 (Pubitemid 351420376)
32. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ (2005) Genetic counseling for fragile X syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 14(4):249-270 (Pubitemid 41095420)
33. Metcalfe S, Barlow-Stewart K, Delatycki MB, Emery JD (2007) Population genetic screening. Aust Fam Physician 36(10):794-800
34. Metcalfe S, Jaques A, Archibald A, Burgess T, Collins V, Henry A, McNamee K, Sheffield L, Slater H, Wake S, Cohen J (2008) A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med 10 (7):525-535
35. Metcalfe SA, Bittles AH, O'Leary P, Emery J (2009) Australia: public health genomics. Public Health Genomics 12(2):121-128
36. National Institutes of Health (1999) Consensus development conference statement on genetic testing for cystic fibrosis. Arch Intern Med 159(14):1529-1539
37. O'Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373 (9678):1891-1904
38. Plass AMC, van El CG, Pieters T, Cornel MC (2010) Neonatal screening for treatable and untreatable disorders: prospective parents' opinions. Pediatrics 125(1):e99
39. Sheeran P, Abraham C (1995) The health belief model. In: Conner M, Norman P (eds) Predicting health behaviour. Open University Press, Buckingham, pp 23-61
40. Sherman S, Pletcher BA, Driscoll DA (2005) Fragile X syndrome: diagnostic and carrier testing. Genet Med 7(8):584-587 (Pubitemid 41566485)
41. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C (2007) A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6(1):57-65 (Pubitemid 46029890)
42. Tercyak KP, Johnson SB, Roberts SF, Cruz AC (2001) Psychological response to prenatal genetic counseling and amniocentesis. Patient Educ Couns 43(1):73-84 (Pubitemid 32331874)
43. van den Berg M, Timmermans DR, ten Kate LP, van Vugt JM, van der Wal G (2006) Informed decision making in the context of prenatal screening. Patient Education and Counseling 63(1-2):110-117 (Pubitemid 44331541)
44. Ziebland S, Herxheimer A (2008) How patients' experiences contribute to decision making: illustrations from DIPEx (personal experiences of health and illness). J Nurs Manag 16(4):433-439